Literature DB >> 19767149

A-kinase anchoring protein 150 controls protein kinase C-mediated phosphorylation and sensitization of TRPV1.

Nathaniel A Jeske1, Amol M Patwardhan, Nikita B Ruparel, Armen N Akopian, Mark S Shapiro, Michael A Henry.   

Abstract

Post-translational modifications on various receptor proteins have significant effects on receptor activation. For the Transient Receptor Potential family V type 1 (TRPV1) receptor, phosphorylation of certain serine/threonine amino acid residues sensitizes the receptor to activation by capsaicin and heat. Although Protein Kinase C (PKC) phosphorylates TRPV1 on certain serine/threonine residues, it is not completely understood how PKC functionally associates with TRPV1. Recent studies have reported that the A-kinase Anchoring Protein 150 (AKAP150) mediates PKA phosphorylation of TRPV1 in several nociceptive models. Here, we demonstrate that AKAP150 also mediates PKC-directed phosphorylation and sensitization of TRPV1. In cultured rat trigeminal ganglia, immunocytochemical analyses demonstrate co-localization of AKAP150 and PKC isoforms alpha, delta, epsilon, and gamma in TRPV1-positive neurons. Additional biochemical evidence supports immunocytochemical results, indicating that AKAP150 preferentially associates with certain PKC isoforms in rat trigeminal ganglia neurons. Employing siRNA-mediated knock-down of AKAP150 expression, we demonstrate that PKC-mediated phosphorylation of TRPV1 and sensitization to a capsaicin response is dependent upon functional expression of the AKAP150 scaffolding protein. Furthermore, PKC-induced sensitization to a thermal stimulus is abrogated in AKAP150 knock-out animals relative to wild-type. Collectively, the results from these studies indicate that the AKAP150 scaffolding protein functionally modulates PKC-mediated phosphorylation and sensitization of the TRPV1 receptor in rat sensory neurons, suggesting the scaffolding protein to be an integral regulator of peripheral inflammatory hyperalgesia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19767149      PMCID: PMC2783249          DOI: 10.1016/j.pain.2009.08.002

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  37 in total

1.  AKAP150 signaling complex promotes suppression of the M-current by muscarinic agonists.

Authors:  Naoto Hoshi; Jia-Sheng Zhang; Miho Omaki; Takahiro Takeuchi; Shigeru Yokoyama; Nicolas Wanaverbecq; Lorene K Langeberg; Yukio Yoneda; John D Scott; David A Brown; Haruhiro Higashida
Journal:  Nat Neurosci       Date:  2003-06       Impact factor: 24.884

2.  The principle of temperature-dependent gating in cold- and heat-sensitive TRP channels.

Authors:  Thomas Voets; Guy Droogmans; Ulrich Wissenbach; Annelies Janssens; Veit Flockerzi; Bernd Nilius
Journal:  Nature       Date:  2004-08-12       Impact factor: 49.962

3.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

4.  Direct phosphorylation of capsaicin receptor VR1 by protein kinase Cepsilon and identification of two target serine residues.

Authors:  Mitsuko Numazaki; Tomoko Tominaga; Hidenori Toyooka; Makoto Tominaga
Journal:  J Biol Chem       Date:  2002-03-07       Impact factor: 5.157

5.  PKA/AKAP/VR-1 module: A common link of Gs-mediated signaling to thermal hyperalgesia.

Authors:  Parvinder Kaur Rathee; Carsten Distler; Otilia Obreja; Winfried Neuhuber; Ging Kuo Wang; Sho-Ya Wang; Carla Nau; Michaela Kress
Journal:  J Neurosci       Date:  2002-06-01       Impact factor: 6.167

6.  Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide.

Authors:  Theodore J Price; Amol Patwardhan; Armen N Akopian; Kenneth M Hargreaves; Christopher M Flores
Journal:  Br J Pharmacol       Date:  2004-03-08       Impact factor: 8.739

7.  Desensitization of capsaicin-activated currents in the vanilloid receptor TRPV1 is decreased by the cyclic AMP-dependent protein kinase pathway.

Authors:  Durga P Mohapatra; Carla Nau
Journal:  J Biol Chem       Date:  2003-09-23       Impact factor: 5.157

8.  Protein kinase C(alpha) is required for vanilloid receptor 1 activation. Evidence for multiple signaling pathways.

Authors:  Zoltan Olah; Laszlo Karai; Michael J Iadarola
Journal:  J Biol Chem       Date:  2002-07-02       Impact factor: 5.157

9.  Contribution of vanilloid receptors to the overt nociception induced by B2 kinin receptor activation in mice.

Authors:  Juliano Ferreira; Gisele L da Silva; João B Calixto
Journal:  Br J Pharmacol       Date:  2004-02-16       Impact factor: 8.739

10.  Protein kinase C phosphorylation sensitizes but does not activate the capsaicin receptor transient receptor potential vanilloid 1 (TRPV1).

Authors:  Gautam Bhave; Hui-Juan Hu; Kathi S Glauner; Weiguo Zhu; Haibin Wang; D J Brasier; Gerry S Oxford; Robert W Gereau
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-01       Impact factor: 11.205

View more
  41 in total

1.  Paclitaxel inhibits the activity and membrane localization of PKCα and PKCβI/II to elicit a decrease in stimulated calcitonin gene-related peptide release from cultured sensory neurons.

Authors:  Lisa M Darby; Hongdi Meng; Jill C Fehrenbacher
Journal:  Mol Cell Neurosci       Date:  2017-04-09       Impact factor: 4.314

Review 2.  Transient receptor potential (TRP) channels: a clinical perspective.

Authors:  Yosuke Kaneko; Arpad Szallasi
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 3.  The mechanism of μ-opioid receptor (MOR)-TRPV1 crosstalk in TRPV1 activation involves morphine anti-nociception, tolerance and dependence.

Authors:  Yanju Bao; Yebo Gao; Liping Yang; Xiangying Kong; Jing Yu; Wei Hou; Baojin Hua
Journal:  Channels (Austin)       Date:  2015-07-15       Impact factor: 2.581

4.  Peripheral group I metabotropic glutamate receptor activation leads to muscle mechanical hyperalgesia through TRPV1 phosphorylation in the rat.

Authors:  Man-Kyo Chung; Jongseok Lee; John Joseph; Jami Saloman; Jin Y Ro
Journal:  J Pain       Date:  2014-11-01       Impact factor: 5.820

Review 5.  Modulation of nociceptive ion channels and receptors via protein-protein interactions: implications for pain relief.

Authors:  Tom Rouwette; Luca Avenali; Julia Sondermann; Pratibha Narayanan; David Gomez-Varela; Manuela Schmidt
Journal:  Channels (Austin)       Date:  2015-06-03       Impact factor: 2.581

6.  Ankyrin-rich membrane spanning protein as a novel modulator of transient receptor potential vanilloid 1-function in nociceptive neurons.

Authors:  J Peter; C Kasper; M Kaufholz; R Buschow; J Isensee; T Hucho; F W Herberg; F Schwede; C Stein; S-E Jordt; M Brackmann; V Spahn
Journal:  Eur J Pain       Date:  2017-02-09       Impact factor: 3.931

7.  A-kinase anchoring protein 150 expression in a specific subset of TRPV1- and CaV 1.2-positive nociceptive rat dorsal root ganglion neurons.

Authors:  Katherine E Brandao; Mark L Dell'Acqua; S Rock Levinson
Journal:  J Comp Neurol       Date:  2012-01-01       Impact factor: 3.215

8.  Corrigendum to "Chronic stress and peripheral pain: Evidence for distinct, region-specific changes in visceral and somatosensory pain regulatory pathways" [Exp Neurol. 2015 Nov.; 273: 301-11].

Authors:  Gen Zheng; Shuangsong Hong; John M Hayes; John W Wiley
Journal:  Exp Neurol       Date:  2016-03-08       Impact factor: 5.330

9.  Targeting the transient receptor potential vanilloid type 1 (TRPV1) assembly domain attenuates inflammation-induced hypersensitivity.

Authors:  Robyn Flynn; Kevin Chapman; Mircea Iftinca; Reem Aboushousha; Diego Varela; Christophe Altier
Journal:  J Biol Chem       Date:  2014-05-07       Impact factor: 5.157

Review 10.  AKAP signaling complexes: pointing towards the next generation of therapeutic targets?

Authors:  Jessica L Esseltine; John D Scott
Journal:  Trends Pharmacol Sci       Date:  2013-11-12       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.